🚀 VC round data is live in beta, check it out!
EQL Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for EQL Pharma and similar public comparables like Cartesian Therapeutics, Protalix, Scancell, TuHURA Biosciences and more.
EQL Pharma Overview
About EQL Pharma
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
Founded
2006
HQ
Employees
21
Website
Sectors
Financials (LTM)
EV
$230M
EQL Pharma Financials
EQL Pharma reported last 12-month revenue of $48M and EBITDA of $9M.
In the same LTM period, EQL Pharma generated $20M in gross profit, $9M in EBITDA, and $3M in net income.
Revenue (LTM)
EQL Pharma P&L
In the most recent fiscal year, EQL Pharma reported revenue of $41M and EBITDA of $9M.
EQL Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $48M | XXX | $41M | XXX | XXX | XXX |
| Gross Profit | $20M | XXX | $17M | XXX | XXX | XXX |
| Gross Margin | 41% | XXX | 42% | XXX | XXX | XXX |
| EBITDA | $9M | XXX | $9M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $3M | XXX | $5M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | — | — | $40M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
EQL Pharma Stock Performance
EQL Pharma has current market cap of $187M, and enterprise value of $230M.
Market Cap Evolution
EQL Pharma's stock price is $6.32.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $230M | $187M | 3.5% | XXX | XXX | XXX | $0.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEQL Pharma Valuation Multiples
EQL Pharma trades at 4.8x EV/Revenue multiple, and 24.3x EV/EBITDA.
EV / Revenue (LTM)
EQL Pharma Financial Valuation Multiples
As of April 18, 2026, EQL Pharma has market cap of $187M and EV of $230M.
Equity research analysts estimate EQL Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
EQL Pharma has a P/E ratio of 65.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $187M | XXX | $187M | XXX | XXX | XXX |
| EV (current) | $230M | XXX | $230M | XXX | XXX | XXX |
| EV/Revenue | 4.8x | XXX | 5.7x | XXX | XXX | XXX |
| EV/EBITDA | 24.3x | XXX | 26.7x | XXX | XXX | XXX |
| EV/EBIT | 33.0x | XXX | 31.9x | XXX | XXX | XXX |
| EV/Gross Profit | 11.6x | XXX | 13.6x | XXX | XXX | XXX |
| P/E | 65.4x | XXX | 39.8x | XXX | XXX | XXX |
| EV/FCF | 111.2x | XXX | (8.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified EQL Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
EQL Pharma Margins & Growth Rates
EQL Pharma's revenue in the last 12 month grew by 37%.
EQL Pharma's revenue per employee in the last FY averaged $1.9M, while opex per employee averaged $0.5M for the same period.
EQL Pharma's rule of 40 is 56% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
EQL Pharma's rule of X is 104% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
EQL Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 37% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 66% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 56% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 104% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.9M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 19% | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | 5% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 24% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
EQL Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| EQL Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Cartesian Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Protalix | XXX | XXX | XXX | XXX | XXX | XXX |
| Scancell | XXX | XXX | XXX | XXX | XXX | XXX |
| TuHURA Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Corbus Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
EQL Pharma M&A Activity
EQL Pharma acquired XXX companies to date.
Last acquisition by EQL Pharma was on XXXXXXXX, XXXXX. EQL Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by EQL Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEQL Pharma Investment Activity
EQL Pharma invested in XXX companies to date.
EQL Pharma made its latest investment on XXXXXXXX, XXXXX. EQL Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by EQL Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout EQL Pharma
| When was EQL Pharma founded? | EQL Pharma was founded in 2006. |
| Where is EQL Pharma headquartered? | EQL Pharma is headquartered in Sweden. |
| How many employees does EQL Pharma have? | As of today, EQL Pharma has over 21 employees. |
| Is EQL Pharma publicly listed? | Yes, EQL Pharma is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of EQL Pharma? | EQL Pharma trades under EQL ticker. |
| When did EQL Pharma go public? | EQL Pharma went public in 2024. |
| Who are competitors of EQL Pharma? | EQL Pharma main competitors are Cartesian Therapeutics, Protalix, Scancell, TuHURA Biosciences. |
| What is the current market cap of EQL Pharma? | EQL Pharma's current market cap is $187M. |
| What is the current revenue of EQL Pharma? | EQL Pharma's last 12 months revenue is $48M. |
| What is the current revenue growth of EQL Pharma? | EQL Pharma revenue growth (NTM/LTM) is 37%. |
| What is the current EV/Revenue multiple of EQL Pharma? | Current revenue multiple of EQL Pharma is 4.8x. |
| Is EQL Pharma profitable? | Yes, EQL Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of EQL Pharma? | EQL Pharma's last 12 months EBITDA is $9M. |
| What is EQL Pharma's EBITDA margin? | EQL Pharma's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of EQL Pharma? | Current EBITDA multiple of EQL Pharma is 24.3x. |
| What is the current FCF of EQL Pharma? | EQL Pharma's last 12 months FCF is $2M. |
| What is EQL Pharma's FCF margin? | EQL Pharma's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of EQL Pharma? | Current FCF multiple of EQL Pharma is 111.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.